Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma

被引:35
作者
Nannetti, Giulio [1 ]
Messa, Lorenzo [1 ]
Celegato, Marta [1 ]
Pagni, Silvana [1 ,2 ]
Basso, Monica [1 ,2 ]
Parisi, Saverio G. [1 ,2 ]
Palu, Giorgio [1 ,2 ]
Loregian, Arianna [1 ,2 ]
机构
[1] Univ Padua, Dept Mol Med, Via Gabelli 63, I-35121 Padua, Italy
[2] Padua Univ Hosp, Clin Microbiol & Virol Unit, Padua, Italy
关键词
Daclatasvir; BMS-790052; HCV NS5A inhibitor; Solid-phase extraction; HPLC-UV; Therapeutic drug monitoring; REPLICATION COMPLEX INHIBITOR; PERFORMANCE LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY METHOD; QUANTITATIVE-DETERMINATION; MS/MS METHOD; BMS-790052; RIBAVIRIN; HIV; ANTIVIRALS; ATAZANAVIR;
D O I
10.1016/j.jpba.2016.11.032
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Daclatasvir is an inhibitor of hepatitis C virus NS5A protein that is used for the therapy of chronic hepatitis. So far, published methods for analysis of daclatasvir in plasma are exclusively based on mass spectrometry, which is not always available in standard clinical laboratories. Thus, we wished to develop and validate a simple, but still reliable and sensitive high-performance liquid chromatography (HPLC) assay with UV detection for the quantification of daclatasvir, feasible for a wide-spread clinical routine use. The method consisted of solid-phase extraction of daclatasvir using Waters Oasis HLB 1cc cartridges, reversed-phase liquid chromatography with a Waters XTerra RP18 (150 mm x 4.6 mm, 3.5 mu m) column and a mobile phase of ammonium acetate buffer (pH 5.0, 10 mM) and acetonitrile (56:44, v/v), and UV detection at 318 nm. This assay proved to be sensitive (lower limit of quantification of 0.05 mu g/mL), linear (correlation coefficients >= 0.997), specific (no interference with various potentially co-administrated drugs), reproducible (both intra-day and inter-day coefficients of variation <8.9%), and accurate (deviations ranged from -2.2 to 8.0% and from -6.5 to 9.2% for intra-day and inter-day assays, respectively). The method was applied to therapeutic monitoring of patients undergoing daclatasvir therapy for hepatitis C and showed to be reliable and robust. Thus, this method provides a simple, sensitive, precise, and reproducible assay for dosing daclatasvir that can be readily adaptable to routine use by clinical laboratories with standard equipment. In addition, the stability of daclatasvir in plasma was evaluated under various conditions, including after the heating procedure required for inactivation of infectious viruses and in different light exposure conditions. These studies evidenced photo-instability of the compound under sunlight exposure over time. Thus, blood sampling and the whole handling procedure have to be performed quickly and with minimal light exposure. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 24 条
[1]  
[Anonymous], 2013, Guidance for industry # 213
[2]   A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma [J].
Ariaudo, Alessandra ;
Favata, Fabio ;
De Nicolo, Amedeo ;
Simiele, Marco ;
Paglietti, Luca ;
Boglione, Lucio ;
Cardellino, Chiara Simona ;
Carcieri, Chiara ;
Di Perri, Giovanni ;
D'Avolio, Antonio .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2016, 125 :369-375
[3]   Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir [J].
Belema, Makonen ;
Nguyen, Van N. ;
Bachand, Carol ;
Deon, Dan H. ;
Goodrich, Jason T. ;
James, Clint A. ;
Lavoie, Rico ;
Lopez, Omar D. ;
Martel, Alain ;
Romine, Jeffrey L. ;
Ruediger, Edward H. ;
Snyder, Lawrence B. ;
St Laurent, Denis R. ;
Yang, Fukang ;
Zhu, Juliang ;
Wong, Henry S. ;
Langley, David R. ;
Adams, Stephen P. ;
Cantor, Glenn H. ;
Chimalakonda, Anjaneya ;
Fura, Aberra ;
Johnson, Benjamin M. ;
Knipe, Jay O. ;
Parker, Dawn D. ;
Santone, Kenneth S. ;
Fridell, Robert A. ;
Lemm, Julie A. ;
O'Boyle, Donald R., II ;
Colonno, Richard J. ;
Gao, Min ;
Meanwell, Nicholas A. ;
Hamann, Lawrence G. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) :2013-2032
[4]   Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir [J].
Bifano, Marc ;
Hwang, Carey ;
Oosterhuis, Berend ;
Hartstra, Jan ;
Grasela, Dennis ;
Tiessen, Renger ;
Velinova-Donga, Maria ;
Kandoussi, Hamza ;
Sevinsky, Heather ;
Bertz, Richard .
ANTIVIRAL THERAPY, 2013, 18 (07) :931-940
[5]   Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients [J].
Burgess, Sarah ;
Partovi, Nilufar ;
Yoshida, Eric M. ;
Erb, Siegfried R. ;
Azalgara, Vladimir Marquez ;
Hussaini, Trana .
ANNALS OF PHARMACOTHERAPY, 2015, 49 (06) :674-687
[6]   Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides [J].
Chukkapalli, Vineela ;
Berger, Kristi L. ;
Kelly, Sean M. ;
Thomas, Meryl ;
Deiters, Alexander ;
Randall, Glenn .
VIROLOGY, 2015, 476 :168-179
[7]   Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus [J].
Chung, Raymond T. ;
Davis, Gary L. ;
Jensen, Donald M. ;
Masur, Henry ;
Saag, Michael S. ;
Thomas, David L. ;
Aronsohn, Andrew I. ;
Charlton, Michael R. ;
Feld, Jordan J. ;
Fontana, Robert J. ;
Ghany, Marc G. ;
Godofsky, Eliot W. ;
Graham, Camilla S. ;
Kim, Arthur Y. ;
Kiser, Jennifer J. ;
Kottilil, Shyam ;
Marks, Kristen M. ;
Martin, Paul ;
Mitruka, Kiren ;
Morgan, Timothy R. ;
Naggie, Susanna ;
Raymond, Daniel ;
Reau, Nancy S. ;
Schooley, Robert T. ;
Sherman, Kenneth E. ;
Sulkowski, Mark S. ;
Vargas, Hugo E. ;
Ward, John W. ;
Wyles, David L. .
HEPATOLOGY, 2015, 62 (03) :932-954
[8]  
European Medicines Agency Daklinza, 2014, EUROPEAN MED AGENCY
[9]   Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations [J].
Fridell, Robert A. ;
Wang, Chunfu ;
Sun, Jin-Hua ;
O'Boyle, Donald R., II ;
Nower, Peter ;
Valera, Lourdes ;
Qiu, Dike ;
Roberts, Susan ;
Huang, Xin ;
Kienzle, Bernadette ;
Bifano, Marc ;
Nettles, Richard E. ;
Gao, Min .
HEPATOLOGY, 2011, 54 (06) :1924-1935
[10]   Diagnosis, Management, and Treatment of Hepatitis C: An Update [J].
Ghany, Marc G. ;
Strader, Doris B. ;
Thomas, David L. ;
Seeff, Leonard B. .
HEPATOLOGY, 2009, 49 (04) :1335-1374